TAK — TAKEDA PHARMACEUTICAL CO LTD catalysts
Next verified catalyst
2026-11-30 — A Study of TAK-360 in Adults With Idiopathic Hypersomnia · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
Phase 2 · Idiopathic Hypersomnia |
TAK TAKEDA PHARMACEUTICAL CO LTD | TAK-360 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Phase 2 · Narcolepsy Type 2 |
TAK TAKEDA PHARMACEUTICAL CO LTD | TAK-360 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-17 in 1mo
ESTIMATED |
READOUT
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
Phase 3 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy |
TAK TAKEDA PHARMACEUTICAL CO LTD | TAK-861 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-01-18 in 3mo
ESTIMATED |
READOUT
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral
Phase 3 · Cytomegalovirus (CMV) |
TAK TAKEDA PHARMACEUTICAL CO LTD | Maribavir |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-02-17 in 4mo
ESTIMATED |
READOUT
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the B
Phase 2 · Crohn's Disease |
TAK TAKEDA PHARMACEUTICAL CO LTD | TAK-279 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2027-03-16 in 4mo
ESTIMATED |
READOUT
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic P
Phase 3 · Thrombotic Thrombocytopenic Purpura (TTP) |
TAK TAKEDA PHARMACEUTICAL CO LTD | TAK-755 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|